A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
← catalyst calendarNCT07365319 · readout in 3,421 d
Sponsored by Eikon Therapeutics (industry) · EIKN — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
750estimated
Sites
18
Countries
Australia, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-15 | actual | When the study began enrolling |
| Primary completion | 2035-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2040-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Stage 4 NSCLC
Interventions
- Drug: EIK1001
- Drug: Pembrolizumab (KEYTRUDA®)
- Drug: Placebo
- Drug: Paclitaxel + Carboplatin
- Drug: Nab-paclitaxel + Carboplatin
- Drug: Pemetrexed + Cisplatin /Carboplatin
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Through study completion, up to 6 years
Overall survival (OS)
measured Through study completion, up to 10 years
Objective Response (OR)
measured Through study completion, up to 6 years
Permalink · EIKN's whole pipeline · Catalyst calendar · Every registered study · What changed